Kidney Cancer Coverage from Every Angle

GU Symposium 2021: Cabozantinib Emerges From SWOG 1500 Trial of Metastatic Papillary Kidney Cancer

By: Sarah Campen, PharmD
Posted: Wednesday, February 24, 2021

Cabozantinib appears to prolong progression-free survival in patients with metastatic papillary renal cell carcinoma compared with sunitinib, according to the multiarm SWOG 1500 trial presented at the 2021 Genitourinary (GU) Cancers Symposium (Abstract 270). Two other MET inhibitors included in the study, crizotinib and savolitinib, did not improve survival outcomes. “For the first time, our study showed that cabozantinib could significantly delay growth and increase the rate of tumor shrinkage in patients as compared to previously utilized agents—in this case, sunitinib,” explained lead study author Sumanta K. Pal, MD, FASCO, of the City of Hope Comprehensive Cancer Center, Duarte, California, in an American Society of Clinical Oncology press release. “The magnitude of the response was surprising,” Dr. Pal added in a SWOG press release.

In this phase II study, 152 patients with metastatic papillary renal cell carcinoma were randomly assigned to receive sunitinib at 50 mg daily (n = 46) for 4 weeks on, 2 weeks off; cabozantinib at 60 mg daily (n = 44); crizotinib at 250 mg twice daily (n = 29); or savolitinib at 600 mg daily (n = 28).

At a pre-planned futility analysis, accrual to the savolitinib and crizotinib arms was halted early; accrual continued to completion in the sunitinib and cabozantinib arms. The median progression-free survival was significantly longer with cabozantinib than with sunitinib at 9.2 months versus 5.6 months (P = .021).

As for safety, grade 3 or 4 adverse events occurred in 69%, 72%, 37%, and 39% of patients receiving sunitinib, cabozantinib, crizotinib, and savolitinib, respectively. One grade 5 adverse event was reported with cabozantinib. “These data support cabozantinib as a reference standard for eligible patients with metastatic papillary renal cell carcinoma,” concluded the authors.

Disclosure: For full disclosures of study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.